Freely Filtered 054: EMPA Kidney!
EMPA-Kidney takes SGLT2i to new frontiers: Lower GFR! No albuminuria! The Filtrate goes deep with Bendon Neuen to tear it apart.
Freely Filtered, a NephJC Podcast · NephJC
Audio is streamed directly from the publisher (static1.squarespace.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The Filtrate:
Joel Topf
Swapnil Hiremath
Josh Waitzman
Sophia Ambruso
Priya Yenebere
With Special Guest:
Brendon Neuen, Secretariat of the SGLT2 Trialists Consortium and cool guy on Twitter.
Editor:
Sophia Ambruso
Show Notes:
Joel’s Conflict of Interest Statement. Sophia is also conflicted with Astra Zeneca and Brendon with everybody in the SGLT2i space.
Joel starts off with a history of SGLT2i
EMPA-REG Outcomes. First!
CANVAS. OMG this signal is reproducible!
CREDENCE (🎧). It works in a dedicated population at high risk of kidney disease. And in a study designed for renal end-points.
DAPA-CKD (🎧). It’s not just for diabetics!
EMPA-Kidney. It works at really low GFR. And without albuminuria. And again in non-diabetics.
SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution
Click to find the supplement (requires a subscription)
Differences in definition in the decreased renal function component of the composite primary outcomes.
EMPA-Kidney 40%
DAPA-Kidney 50%
CREDENCE doubling of serum Cr
Usability Testing of a Sick-Day Protocol in CKD (Pubmed)
New Guidelines for Statistical Reporting in the Journal (link, commentary on said guidelines by Frank Harrell)
The Peripheral on Amazon Prime
Unsealed the Tylenol Murders Podcast
Project Hail Mary by Andrew Weir
Lizzy McAlpine Singer Song Writer
Rachel Maddow Presents: Ultra
Twitter chaos continues. Get your Med-Mastodon handle